Rexall and Novo Nordisk Canada launch home delivery for Ozempic, Wegovy and Rybelsus

Rexall and Novo Nordisk Canada have launched Novo Nordisk Care Rx, a home delivery service for the semaglutide brands Ozempic, Wegovy and Rybelsus ^[1]. The service covers every Canadian province and territory except Quebec, according to the announcement dated August 21, 2026 ^[1].

Ozempic, Wegovy and Rybelsus are Novo Nordisk's three semaglutide products, packaged and dosed differently rather than being different molecules ^[1]. The new channel delivers those brand products to patients' homes instead of requiring a pharmacy pickup, the listing states ^[1].

Quebec is not included. The province was also left out of a Novo Nordisk Canada savings card for Ozempic announced earlier in August, which aligned brand pricing with generics for uninsured Canadians and was run through Rexall pharmacies ^[1]. No reason for Quebec's exclusion from either program has been reported, and no date has been announced for adding the province.

The delivery launch lands as generic semaglutide reaches the Canadian market. Health Canada has approved three of nine generic semaglutide products, according to the generic tracker cited in the same news feed ^[1]. Novo Nordisk has guided to a 5 to 13 percent revenue decline in 2026 as Canadian generic semaglutide reaches pharmacies, and reporting describes the company as defending brand volumes through savings cards ^[1].

Price is the backdrop. Under Canada's pCPA tiered pricing, a first generic entrant is priced at 75 to 85 percent of the brand price, and that falls to 35 percent once three or more generics are on the market ^[1]. Canadian benefits plans have been preparing for a 65 percent list-price cut once a third generic semaglutide launches ^[1].

Why it matters for patients

This is a Canadian distribution change, and no US price, insurance or pharmacy-access effect tied to it has been reported ^[1]. Patients in the United States should not expect their own fills or copays to change because of it.

What the launch does show is how a brand manufacturer is trying to hold on to patients as cheaper copies arrive. Rather than competing only on price at the pharmacy counter, Novo Nordisk Canada is pairing a discounted brand price for uninsured Canadians with a delivery channel run through one retail partner ^[1]. For Canadian patients who prefer the brand product, that combination may be an alternative to switching, though the reporting does not say what the delivery service itself costs or whether it carries a shipping fee.

Several practical questions are unanswered. It has not been disclosed whether provincial drug plans or private insurers cover the delivery service, how cold-chain handling works during shipment, whether any pharmacy other than Rexall can fill orders, or whether the program will eventually include Quebec.

What happens next

Counts of the generic semaglutide queue have differed across reports. One early-August report said seven generic semaglutide files were still awaiting a Health Canada decision ^[1], while the generic tracker says three of nine products are approved ^[1]. Health Canada has not announced dates for the remaining decisions.

The timing of the third generic matters because it is the trigger for the deepest price tier, a cut described as roughly 65 percent off the brand list price ^[1]. No launch date for a third generic has been confirmed in the reporting. Novo Nordisk has also not said whether the savings card or the delivery service will expand to Quebec ^[1].